Author/Authors :
TANYILDIZI, Rumeysa Fırat Üniversitesi - Tıp Fakültesi - Göz Hastalıkları Anabilim Dalı, TÜRKİYE , TURGUT, Burak Fırat Üniversitesi - Tıp Fakültesi - Göz Hastalıkları Anabilim Dalı, TÜRKİYE
Abstract :
Objectives: To evaluate the effects of intravitreal bevacizumab injection on visual and foveal thickness in patients with refractory diabetic macular edema. Material and Methods: Between January 2010 to February 2011, twenty eye units of 15 patients with diffuse diabetic macular edema were evaluated retrospectively. Eyes with diffuse diabetic macular edema with foveal thickness greater than 350 μm revealed by optical coherence tomography (OCT) were performed 1.25 mg/0,05 ml intravitreal bevacizumab injection. The mean follow-up period was 9±3 months. Visual acuity (log-MAR), anterior segment, fundus, OCT were evaluated before the injection and 1, 3, 6 months after the injection, Results: Six patients (%40) female and 9 (%60) were female. The mean age was 51.4±7.4. The mean visual acuity (log-MAR) of the patients before treatment 1.0±0.67, 1 months after treatment 0.8±0.5, 3 months after treatment 0.7±0.4, 6 months after treatment 0.6±0.4 respectively. The best visual acuity was increased in 10 (%50) eyes, but was not changed in seven (%35) eyes and decreased in three (%15) eyes after bevacizumab injection. The mean central foveal thickness before treatment, 1st, 3rd and 6th months after injection was 690±90μm, 300±84μm, 290±84 μm and 260±41μm respectively. Twelve eyes (%60) had reduced macular edema but not changed in 5 (%25) eyes and increased in 3 (%15) eyes. Repeated injection were needed for five eyes during the follow up period. Conclusion: We observed prevention of vision loss and anatomical improvement with OCT in patients with intravitreal bevacizumab injection for diffuce refractory diabetic macular edema.
